NCT07325136RecruitingPhase 1/2
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 6 Jan 2026
- Start date
- 3 Feb 2026
- Primary completion date
- 23 Apr 2029
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Lung cancer
- NCT number
- NCT07325136
- EU CT number
- 2025-524090-16-00
- EudraCT number
- 2025-524090-16
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 240
- From 3 Feb 2026 to the primary completion date, 23 Apr 2029
- 13 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants must not have had a prior organ or tissue allograft.
Other illness
- Participants must not have an active, known or suspected autoimmune disease.
Other
- Participants must not have any untreated CNS metastases.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Who the study is looking for
- Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
- Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
- In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Local Institution - 0029 Coordinator of this site? Confirm its status | Beijing | China | Not yet recruiting |
| Shanghai East Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Humanitas Mirasole S.p.A. Coordinator of this site? Confirm its status | Rozzano | Italy | Recruiting |
| Local Institution - 0018 Coordinator of this site? Confirm its status | Chuo-ku | Japan | Not yet recruiting |
| Local Institution - 0020 Coordinator of this site? Confirm its status | Hirakata | Japan | Not yet recruiting |
| Centrul De Oncologie SF Nectarie S.R.L. Coordinator of this site? Confirm its status | Craiova | Romania | Recruiting |
| Oncohelp Medical Center Coordinator of this site? Confirm its status | Timișoara | Romania | Recruiting |
| Roswell Park Cancer Institute Coordinator of this site? Confirm its status | Buffalo | United States | Recruiting |
| University Hospitals Cleveland Medical Center* Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| Karmanos Cancer Institute Coordinator of this site? Confirm its status | Detroit | United States | Recruiting |
| Duke Cancer Institute Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
| SCRI Oncology Partners Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.